Dr. Reddy's Gets VAI Classification for Hyderabad Unit

DRREDDY 'S LABORATORIES: Dr. Reddy's Laboratories has received a Voluntary Action Indicated (VAI) classification from the United States Food and Drug Administration (USFDA) following a Good Manufacturing Practices (GMP) inspection at its formulations manufacturing facility, FTO-3, located in Bachupally, Hyderabad. The company informed the stock exchanges that the USFDA has classified the inspection outcome as VAI and officially closed the inspection under 21 CFR 20.64(d)(3). The inspection was conducted between August 6 and August 14, 2026, and the company had earlier disclosed that it received a Form 483 containing four observations. The company subsequently provided its responses within the stipulated timeline. The latest update confirms the regulatory classification and formal closure of the inspection process. VAI stands for Voluntary Action Indicated and represents the USFDA's classification of the inspection outcome. This is a regulatory development relating specifically to the FTO-3 formulations facility in Hyderabad. The outcome is an important corporate update for Dr. Reddy's Laboratories, particularly in the context of regulatory compliance and manufacturing operations. Market participants may track further regulatory disclosures and company updates for developments concerning its manufacturing facilities. Overall, the USFDA has classified the FTO-3 Hyderabad facility inspection as VAI and confirmed its official closure, following the GMP inspection conducted in August 2026. This information is shared strictly as a corporate and market update for informational purposes and should not be considered investment advice, research analysis, or a recommendation to buy or sell any security.